Compare common side effects, interactions, warnings, and more.
Tirzepatide
*image for illustrative purpose only
Mounjaro
*image for illustrative purpose only
Tirzepatide
*image for illustrative purpose only
Mounjaro
*image for illustrative purpose only
Tirzepatide is the active ingredient in the brand-name medication Mounjaro®. The information below is about brand name Mounjaro. According to the FDA, “Generic medicines use the same active ingredients as brand-name medicines and work the same way, so they have the same risks and benefits as the brand-name medicines.”
Mounjaro (tirzepatide) is an injectable medication used to treat type 2 diabetes by improving blood sugar control and promoting weight loss. It functions by activating two receptors, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which enhance insulin secretion and slow gastric emptying. Mounjaro is administered once weekly, with dose adjustments made based on the patient's response. Common side effects include nausea, diarrhea, and decreased appetite. It should be used with caution in individuals with a history of thyroid cancer or multiple endocrine neoplasia syndrome type 2.
Mounjaro® (tirzepatide) is an injectable medication used to treat type 2 diabetes by improving blood sugar control and promoting weight loss. It functions by activating two receptors, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which enhance insulin secretion and slow gastric emptying. Mounjaro is administered once weekly, with dose adjustments made based on the patient's response. Common side effects include nausea, diarrhea, and decreased appetite. It should be used with caution in individuals with a history of thyroid cancer or multiple endocrine neoplasia syndrome type 2.
Glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist
Glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist
Mounjaro (tirzepatide) is indicated:
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Mounjaro (tirzepatide) is indicated:
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Typically taken as an injection once weekly
Comes in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per 0.5 mL single-dose pens or single-dose vials
Typically taken as an injection once weekly
Comes in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg per 0.5 mL single-dose pens or single-dose vials
The most common adverse reactions, reported in ≥5% of patients treated with Mounjaro are:
Nausea
Diarrhea
Decreased appetite
Vomiting
Constipation
Indigestion
Abdominal pain
The most common adverse reactions, reported in ≥5% of patients treated with Mounjaro are:
Nausea
Diarrhea
Decreased appetite
Vomiting
Constipation
Indigestion
Abdominal pain
Personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome type 2
Known serious hypersensitivity to tirzepatide or any of the excipients in Mounjaro
Drug interactions: Mounjaro delays gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications
Personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome type 2
Known serious hypersensitivity to tirzepatide or any of the excipients in Mounjaro
Drug interactions: Mounjaro delays gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications
Pancreatitis
Low blood sugar with concomitant use of insulin secretagogues or insulin
Hypersensitivity reactions
Acute kidney injury
Severe gastrointestinal disease
Diabetic retinopathy complications in patients with a history of diabetic retinopathy
Acute gallbladder disease
Pregnancy: Based on animal study, may cause fetal harm
Females of reproductive potential: Females using oral contraceptives should consider switching to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation
Pancreatitis
Low blood sugar with concomitant use of insulin secretagogues or insulin
Hypersensitivity reactions
Acute kidney injury
Severe gastrointestinal disease
Diabetic retinopathy complications in patients with a history of diabetic retinopathy
Acute gallbladder disease
Pregnancy: Based on animal study, may cause fetal harm
Females of reproductive potential: Females using oral contraceptives should consider switching to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation
WARNING: RISK OF THYROID C-CELL TUMORS
Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether Mounjaro causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.
Mounjaro is contraindicated in patients with a personal or family history of MTC or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors.
WARNING: RISK OF THYROID C-CELL TUMORS
Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether Mounjaro causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.
Mounjaro is contraindicated in patients with a personal or family history of MTC or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors.
*This information is from the label for brand name Mounjaro. See the Full Prescribing Information for more complete information. Tirzepatide, the active ingredient in Mounjaro, may also be the active ingredient in other medications, and this information may not be accurate for all medications that include the active ingredient tirzepatide.
*This information is from the label for brand name Mounjaro. See the Full Prescribing Information for more complete information. Tirzepatide, the active ingredient in Mounjaro, may also be the active ingredient in other medications, and this information may not be accurate for all medications that include the active ingredient tirzepatide.